Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
Research compound science uses precise terminology drawn from biochemistry, pharmacology, endocrinology, and analytical chemistry. This glossary defines the terms most commonly encountered in peptide research, androgen pharmacology, GLP-1 axis research, and quality testing documentation. Terms are organized alphabetically within category sections.
Peptide Chemistry & Structure#
Amino acid (AA): The building block of peptides and proteins. 20 standard amino acids are encoded by the genetic code; each has a unique side chain (R-group) that determines its chemical properties. Abbreviated by one- (G, A, V…) or three-letter (Gly, Ala, Val…) codes.
Peptide bond: The covalent bond formed between the carboxyl group (-COOH) of one amino acid and the amino group (-NH2) of the next, with loss of water. All peptide chains are linked by peptide bonds.
N-terminus / C-terminus: The free amino group end (N-terminus) and free carboxyl group end (C-terminus) of a peptide chain. Peptide sequences are written N→C (left to right) by convention.
Peptide: A chain of 2–50 amino acids linked by peptide bonds. Larger chains (50+ AAs) are typically called proteins, though the boundary is not strict.
SPPS (Solid-Phase Peptide Synthesis): The standard method for synthesizing research peptides. Amino acids are added sequentially to a resin support, one at a time, using protecting groups to prevent unwanted reactions. The completed peptide is cleaved from the resin and purified by HPLC.
Lyophilization (freeze-drying): The process of removing water from a solution by freezing it and then sublimating the ice under vacuum. Research peptides are supplied as lyophilized powder to maximize stability — water accelerates peptide degradation via hydrolysis.
Reconstitution: Adding solvent (typically bacteriostatic water or saline) to a lyophilized peptide to produce a solution for research use. The lyophilized form is stable; the reconstituted solution has a shorter shelf life.
Molecular weight (MW): The sum of the atomic masses of all atoms in a molecule, expressed in Daltons (Da) or g/mol. Used for identity verification via mass spectrometry (measured MW should match theoretical MW within 0.1 Da for a pure, correctly synthesized peptide).
Analytical Chemistry & Quality Testing#
HPLC (High-Performance Liquid Chromatography): The primary method for determining peptide purity. The sample is injected into a solvent stream flowing through a column containing a stationary phase; compounds separate by differential interaction with the stationary phase and are detected by UV absorbance (typically 214–220 nm for peptide bonds). Purity is reported as area% of the target compound peak.
Area% (HPLC): The fraction of total UV absorbance area attributable to the target compound's peak. Area% = (target peak area / sum of all peak areas) × 100. A value of 98% means 98% of UV-absorbing material is the target compound.
RP-HPLC (Reverse-Phase HPLC): The most common HPLC mode for peptide analysis. The stationary phase is non-polar (C18 or C8 carbon chains); more hydrophobic compounds elute later. Standard for peptide purity determination.
ESI-MS (Electrospray Ionization Mass Spectrometry): An ionization method that gently ionizes large molecules (including peptides) without fragmentation. Produces multiply-charged ions in solution → multiple m/z peaks (charge state envelope). Used to confirm peptide molecular weight and identity.
m/z (mass-to-charge ratio): The value measured in mass spectrometry. For a peptide of molecular weight M with charge z, the observed m/z = (M + z × 1.0073) / z. A peptide of MW 1000 Da with a 2+ charge would give m/z ≈ 501.
LAL test (Limulus Amebocyte Lysate): The standard method for endotoxin quantification. Lysate from horseshoe crab blood cells (Limulus polyphemus) reacts with bacterial endotoxins (lipopolysaccharide, LPS), causing clotting. Results reported in EU/mL (endotoxin units per mL) or EU/mg.
Endotoxin (EU): Endotoxin units — the standard measure of bacterial LPS contamination. Endotoxin contamination in research compounds causes inflammatory responses in animal models that confound experimental results. EU/mg for peptide powders; EU/mL for injectable solutions.
COA (Certificate of Analysis): A document from a testing laboratory reporting the analytical results for a specific batch of compound. Should include: compound name, batch number, testing date, testing methods, and numerical results for each parameter (purity, identity, endotoxin, etc.).
NMR (Nuclear Magnetic Resonance): A spectroscopic technique providing structural information by detecting the magnetic resonance of atomic nuclei (typically ¹H and ¹³C). Can confirm amino acid sequence and stereochemistry for peptides; used for selected high-value compounds where MS identity alone is insufficient.
Pharmacokinetics & Pharmacodynamics#
PK (Pharmacokinetics): What the body does to the compound — absorption, distribution, metabolism, excretion (ADME). Key PK parameters include half-life, Tmax, Cmax, AUC, and bioavailability.
PD (Pharmacodynamics): What the compound does to the body — receptor binding, downstream signaling, and measurable biological effects. EC50, Emax, and potency are PD parameters.
Half-life (t½): The time for the plasma concentration of a compound to decrease by 50% from any given value. For first-order elimination kinetics: t½ = 0.693 / elimination rate constant (ke). After 5 half-lives, approximately 97% of the compound has been eliminated.
Tmax: The time at which plasma concentration reaches its maximum (Cmax) after administration. For SC-injected peptides, Tmax is typically 15–60 minutes.
AUC (Area Under the Curve): The integral of plasma concentration over time, representing total systemic drug exposure. Used to compare bioavailability between routes or formulations.
Bioavailability (F): The fraction of administered dose that reaches systemic circulation unchanged. IV = 100% by definition. SC bioavailability of peptides: typically 50–90% depending on molecular weight and formulation.
Volume of distribution (Vd): A pharmacokinetic parameter describing how widely a compound distributes in the body. Vd = dose / plasma concentration at t=0. High Vd (>10 L/kg) indicates extensive tissue distribution.
Clearance (CL): The volume of plasma cleared of compound per unit time (L/h or mL/min). CL = dose / AUC. Total clearance combines renal, hepatic, and other elimination routes.
Receptor Pharmacology#
Agonist: A compound that binds to a receptor and activates it, producing a biological response. Full agonists produce maximal response; partial agonists produce sub-maximal response even at full receptor occupancy.
Antagonist: A compound that binds to a receptor and blocks agonist binding without activating the receptor. Competitive antagonists compete with agonists for the same binding site (effect is reversible with higher agonist concentration).
EC50: The concentration of agonist producing 50% of the maximal response (Emax). Lower EC50 = higher potency.
IC50: The concentration of antagonist/inhibitor producing 50% inhibition of a response. Lower IC50 = higher potency as an inhibitor.
GPCR (G Protein-Coupled Receptor): The largest family of cell-surface receptors, all sharing a 7-transmembrane domain structure. Most peptide hormone receptors are GPCRs: GLP-1R, GHSR-1a (ghrelin/ipamorelin), GHRHR (CJC-1295), melanocortin receptors (PT-141), GnRH receptor.
Gαs / Gαi / Gαq: The three main G protein alpha subunits. Gαs activates adenylyl cyclase → cAMP increase; Gαi inhibits adenylyl cyclase → cAMP decrease; Gαq activates phospholipase C → IP3/DAG → Ca²⁺ release. GLP-1R signals primarily via Gαs.
cAMP (cyclic AMP): A second messenger produced by adenylyl cyclase upon Gαs activation. cAMP activates PKA (protein kinase A), which phosphorylates multiple substrates including CREB (gene expression), KATP channels (insulin secretion), and HSL (lipolysis).
Downregulation / Desensitization: Reduced receptor expression (downregulation) or reduced responsiveness to agonist (desensitization) after sustained exposure. Mediated by receptor internalization (endocytosis) or GRK/β-arrestin phosphorylation. Relevant to research protocol design for chronic compound administration.
Semaglutide, €43 · 99.0% purityEndocrinology & Axis Terminology#
HPTA (Hypothalamic-Pituitary-Testicular Axis): The hormonal cascade controlling testosterone production: GnRH (hypothalamus) → LH/FSH (pituitary) → testosterone (Leydig cells in testes). Anabolic steroids suppress this axis through negative feedback.
GH axis: Growth hormone-releasing hormone (GHRH) from hypothalamus and ghrelin/GHSRs from stomach → GH (pituitary) → IGF-1 (liver, tissues). Ipamorelin and CJC-1295 target different points on this axis.
Negative feedback: The hormonal mechanism where downstream hormones inhibit upstream signals to maintain homeostasis. Testosterone/E2 → inhibit GnRH and LH/FSH. IGF-1 → inhibits GH secretion. This feedback is the basis for HPTA suppression during androgen research.
Aromatase (CYP19A1): The enzyme that converts androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). Present in adipose tissue, liver, brain, and gonads. Aromatase inhibitors (anastrozole, letrozole) block this conversion.
5α-reductase: The enzyme that converts testosterone to dihydrotestosterone (DHT), a more potent AR agonist. Two isoforms (Type 1: skin/liver; Type 2: prostate/genital skin). Nandrolone is converted by 5α-reductase to DHN (dihydronandrolone), which is weaker than nandrolone — the opposite of testosterone's conversion to DHT.
Somatopause: The age-related decline in GH pulse amplitude and IGF-1 levels. Beginning in the third decade, GH secretion declines approximately 15% per decade. Somatopause research targets include GHSR-1a agonists (ipamorelin) and GHRH analogs (CJC-1295).
Research Design Terminology#
DIO model (Diet-Induced Obesity): A rodent obesity model created by feeding high-fat diet (typically 45–60% fat by calories) to mice or rats for 8–16 weeks. C57BL/6J mice are particularly susceptible to DIO. Standard model for metabolic compound research.
Castrated rat model: A rodent model in which testes are surgically removed to eliminate endogenous testosterone. Used in androgen research to ensure all androgenic effects observed are attributable to the exogenous compound, not confounded by endogenous hormone.
Randomized controlled trial (RCT): An experiment in which subjects are randomly assigned to treatment vs. control groups. Randomization eliminates selection bias. The gold standard for determining causal effects.
Positive control: A treatment group that is expected to produce a known effect, included to verify the experimental system is working. In a wound-healing peptide study, a positive control might be a compound with established efficacy (e.g., VEGF protein).
Vehicle control: A control group receiving the same solvent/carrier as the treatment group, without the active compound. Ensures any observed effects are due to the compound rather than the solvent.
Endpoint: A measured outcome in a research study. Primary endpoints are the main outcomes the study is designed to detect; secondary endpoints provide additional information. Examples: body weight (primary in DIO models), serum IGF-1 (primary in GH axis research), tendon tensile strength (primary in BPC-157 tendon repair models).
Research Use Only. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · October 2026 · Category: Research Protocols & Science
